Cell and Gene therapy provides great promise to treat many diseases, such as B-cell malignancies, with FDA-approved CAR-T cells. Immune cells are first isolated from the patient or donor, followed by activation, expansion, and ex vivo genetic modification of selected immune cells. It is important to control and monitor the quantity and quality of immune cells throughout the development process as well as in the final product release phase as recommended by the Chemistry, Manufacturing, and Control (CMC) FDA guidelines.
In this webinar, Dr. Kevin Travers, from LevitasBio. Inc. will present a novel technology and optimized workflows to enrich primary cells from various challenging samples without damaging fragile cells.
Our 2nd speaker, Dr. Leo Chan, from Nexcelom Bioscience will describe optimized real-time apoptosis assays for 2D or 3D in vitro cell culture samples performed on the Cellaca® PLX and Celigo high-throughput cell counting and image cytometry systems.
[button link=”https://register.gotowebinar.com/register/3404228066462063707?source=W_LevitasBio” class=”short_code” type=”small” color=”blue”] Register Here[/button]